Presentation is loading. Please wait.

Presentation is loading. Please wait.

Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.

Similar presentations


Presentation on theme: "Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012."— Presentation transcript:

1 Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012

2 Objectives Understand why collaborative staging was created Learn the concepts of collaborative staging for breast cases

3 Collaborative Staging 5yr group effort among all standard setters in North America Designed by and for cancer registrars to code the facts about a cancer case General rules apply to all sites/histologies unless superseded by site-specific rule

4 Collaborative Staging Used for cases diagnosed 1/1/2004 and forward – CSv2 for cases diagnosed 1/1/2010 and forward Derives: – AJCC TNM – SEER Summary Understand SEER Summary and TNM is necessary in order to analyze cases

5 Collaborative Staging Allows both clinical and pathologic information to be used to determine stage – Pathologic information takes precedence

6 Collaborative Staging CS Solution: Mixed or “Best Staged” – Result: more relevant to actual practice – Fewer unstageable cases Registrar records : T elements + c/p N elements + c/p M elements + c/p Site Specific Factors (tumor markers) c/pT c/p N c/p M And Stage Group SS77, SS2000 Computer Derives:

7 Data Elements: CS Tumor Size CS Extension CS TS/Exten Eval CS Lymph Nodes CS LN Eval Regional LN Positive Regional LN Exam CS Mets @ DX CS Mets Eval SSF 1-25

8 Breast CS

9 Collaborative Staging Evaluation Fields: – Code based on the procedure performed Scans Biopsies Surgery – Derives the TNM as clinical or pathologic

10 Breast Evaluation Codes CODEDESCRIPTIONSTAGING 0Physical Exam; Imagingc 1Diagnostic BX; FNAc 3Resection without neoadjuvant TXp 5Neoadjuvant TX; Based on Clinical information c 6Neoadjuvant TX; Resection informationyp 9Unknownc

11 Breast CS Data Items Tumor Size Extension Lymph Nodes Lymph Node Positive/Exam Distant Mets at Diagnosis Site Specific Factors 1-24

12 Tumor Size/Extension

13 Tumor Size Code the specific size of the tumor in mm – Convert any size in cm to mm Pathologic size: – Take pathologic size over clinical – Record the invasive size Example: Invasive Ductal Carcinoma, 0.5cm; DCIS, 2cm Code Tumor Size: 005

14 Tumor Size Special Codes: – 990 Microinvasion; Microscopic focus – 991-995 No specific size: “less than ___cm” – 996 seen on mammogram only but no size given – 997 Paget’s of nipple, no underlying tumor – 998 Diffuse

15 Extension In Situ only: 000 – No invasive disease Invasive cancer without skin involvement: 100 Skin involvement: 200 – Adherence, Attachment, Fixation, Induration & Thickening – Without diagnosis Inflammatory Breast CA

16 CS BREAST: EXTENSION Example: L breast partial mastectomy Path report partial mastectomy: 2cm invasive ductal carcinoma invading into skin CS Extension: 200 (invade skin)

17 Extension Inflammatory Breast CA: – Based on clinical information – Codes based on percentage of breast involved: Code 600: 33% or less Code 725: more than 33% but less than 50% Code 730: more than 50% Code 750*: percentage unknown *Most common code for IBC

18 Regional Lymph Nodes

19 Lymph Nodes Regional Lymph Nodes Only: – Do NOT code cervical or contralateral axillary LN – Includes Levels 1-3 Ipsilateral Axillary LN, internal mammary LN and Supraclavicular LN – Clinical vs. Pathologic If the only information about involved regional LN is from physical exam or imaging- clinical If there are positive LN found on sampling/dissection- pathologic

20 Level 1 & 2 Axilla LN Code 250: – Pathologic involvement LN Code 255: – Clinical involvement moveable LN Code 510: – Clinical involvement fixed/matted LN Code 520: – Pathologic involvement fixed/matted LN Code 600: – Axillary, NOS

21 CS BREAST: LYMPH NODES Example: R breast modified radical mastectomy (MRM) Path from R MRM: 3cm invasive ductal carcinoma; 2/4 R axillary LN involved with metastatic disease CS LN: 250 (pathologic positive movable axillary LN)

22 Reg LN Positive Record all positive pathologic examined regional lymph nodes Example: 3/5 R axillary LN involved with invasive duct carcinomaCODE: 03 Code 95: – Positive LN only on core biopsy or FNA Code 98: – No regional LN were examined pathologically

23 Reg LN Examined Record the total number of pathologically examined regional LN Example: 3/5 R axillary LN involved with invasive duct carcinomaCODE: 05 Code 95: – Regional LN examined by core biopsy or FNA only Code 00: – No regional LN examined pathologically

24 Distant Mets at Diagnosis

25 Distant Mets Code 00: – No evidence of metastatic disease Code 10: – Involvement distant LN: Cervical Contralateral/Bilateral Axillary and/or internal mammary LN Code 40: – Distant met site except distant LN

26 Distant Mets Code 42: – Further contiguous extension: Skin over axilla, contralateral breast, sternum, upper abdomen Code 44: – Involve any of the following: Adrenal gland Bone Contralateral breast- if stated metastatic Lung Ovary Sat nodules skin other than primary breast

27 Distant Mets Code 50: – Distant LN – Distant Sites (listed in codes 40-44) Code 60: – Distant mets, NOS

28 CS BREAST: METS AT DX Example R breast with palpable mass 4cm with fixed R axillary LN mass. CT AB/Pelvis: Innumerable liver mets CS Mets @ DX: 40 (Distant mets other than distant LN)

29 Site Specific Factors

30 Collaborative Staging Site-Specific Factors – Not all 25 SSF are used for every case Breast has the most with 24 to complete – Additional information needed to derive TNM – Prognostic Tumor Markers/Labs – Special Interest/Future Research – Other clinically significant information

31 SSF 1: ER & SSF 2: PR If there is any sample positive, record as positive Do NOT record ER results from Oncotype DX or other multigene test 010- Positive 020- Negative 997- Test ordered results not in chart 999- Unknown

32 SSF 3: Pos Level 1 & 2 LN Based on pathologic information ONLY Code 098: – No pathologically examined LN Code 000: – Negative LN Code 001-089: – Code the exact number of positive LN Code 095: – Positive LN by biopsy or FNA

33 SSF 7: BR Score Priority Order: – BR Score – BR Grade Codes 030-090: – BR Score range of 3-9 Codes 110-130: – BR Grade: Low, Intermediate, High Code 998: – No histologic exam of primary tumor

34 HER 2 SSF 8: IHC test value – Scores 0, 1+, 2+, 3+ SSF 9: IHC interpretation – Record the pathologists interpretation of the test value: positive, negative, equivocal SSF 10: FISH value – Record ratio as given – Code 991: ratio less than 1.00 SSF 11: FISH interpretation – Record the interpretation of the test value

35 HER 2 SSF 14: Other/Unknown test – Statement in medical record on HER2, unknown type of testing performed – Other type of test performed SSF 15: Summary of results – Based on codes in SSF 9, 11, 13 and 14 – Both IHC and FISH/CISH record results of FISH/CISH Except when IHC is performed to clarify equivocal test of FISH/CISH

36 SSF 16: ER, PR & HER2 Identifies Triple negative patients Code Pattern: – First digit: ER – Second digit: PR – Third digit: HER2 Digits: – 0= negative – 1= positive Information unknown on one or more test code 999

37 SSF 16 Example: ER: positive (SSF1: 010) PR: positive (SSF2: 010) HER2: negative (SSF 15: 020) SSF 16 Code: 110 Triple Negative patients code 000

38 SSF 22: Multigene Method Assess: – likelihood of response to chemotherapy – evaluate prognosis or distant recurrence Code 010: Oncotype DX Code 020: MammaPrint Code 030: Other test

39 SSF 23: Multigene Result Record the results of the multigene method: – Oncotype DX: Scores range 0-100 – MammaPrint: Low Risk or High Risk Codes 000-100 – Record actual Oncotype DX score Code 200: Low Risk Code 300: Intermediate Risk Code 400: High Risk

40 SSF 24: Paget’s Disease Record any mention of Paget’s disease – Pathologic takes precedence over clinical info Negative exam of nipple – Interpret as no Paget’s disease Pathology report mentions pagetoid involvement of nipple, Code 020 – Does NOT include pagetoid involvement of ducts or lobules

41 Current Version CSv02.04 http://www.cancerstaging.org/cstage/manuals/coding0204.html Additional Help: http://cancerbulletin.facs.org/forums/

42 The Whole Picture Now you can put these pieces together while using the CS Manual to create a beautiful picture! Always read your notes for CS, they are the little pieces that create the whole!

43 Thank You! Melissa Riddle, RHIT, CTR melissariddlespeaks@ymail.com


Download ppt "Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012."

Similar presentations


Ads by Google